Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2025
Description
DelveInsight’s, “Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Acute On Chronic Liver Failure (ACLF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute On Chronic Liver Failure (ACLF): Overview
Acute on chronic liver failure is a clinical syndrome of sudden hepatic decompensation observed in patients with pre-existing chronic liver disease. Acute on chronic liver failure is a serious condition with very high morbidity and mortality.
The pathophysiology is based on the understanding that an acute precipitating event in a patient with a chronic liver condition that injures hepatocytes leads to the accumulation of a cascade of inflammatory cytokines and results in further hepatic injury in the presence of failure of hepatocyte regeneration. The resulting compromise in immune function and liver decompensation leads to further susceptibility to infections, multi-organ failure, and death.
Patients will have features of acute hepatic decompensation. Also common are prolonged INR greater than or equal to 1.5, often elevated bilirubin and aminotransferases, thrombocytopenia with anemia, hypoglycemia, elevated ammonia, features of acute renal injury (with elevated serum creatinine), and abnormal electrolytes (hypokalemia, hypophosphatemia). Any imaging to support the clinical examination findings and ascertain infection or any organ involvement or organ failure may be required. Imaging of the brain, chest, abdomen, and pelvis should be considered. Abdominal imaging to determine the presence of features of portal hypertension, hepatocellular carcinoma, vascular thrombosis, lymph nodes, and spleen is vital. Abdominal sonogram with Doppler could be considered in patients with concomitant renal injury and vascular thrombosis. Brain imaging (CT or MRI) is helpful to rule out organic etiology of altered mental status, while chest imaging will help rule out pulmonary edema or pneumonia.
The management of ACLF consists of the prevention of precipitating factors leading to acute hepatic decompensation, supportive care, and early initiation of specific therapy, prevention, and management of complications. It also includes determining the prognosis and the need for liver support including possible liver transplantation. All patients should be hospitalized preferably at a center that has facilities and expertise for a liver transplant.
""Acute On Chronic Liver Failure (ACLF)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure (ACLF) pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure (ACLF) treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure (ACLF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure (ACLF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acute On Chronic Liver Failure (ACLF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute On Chronic Liver Failure (ACLF) Emerging Drugs
Further product details are provided in the report……..
Acute On Chronic Liver Failure (ACLF): Therapeutic Assessment
This segment of the report provides insights about the different Acute On Chronic Liver Failure (ACLF) drugs segregated based on following parameters that define the scope of the report, such as:
Acute On Chronic Liver Failure (ACLF): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure (ACLF) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure (ACLF) drugs.
Acute On Chronic Liver Failure (ACLF) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Acute On Chronic Liver Failure (ACLF): Overview
Acute on chronic liver failure is a clinical syndrome of sudden hepatic decompensation observed in patients with pre-existing chronic liver disease. Acute on chronic liver failure is a serious condition with very high morbidity and mortality.
The pathophysiology is based on the understanding that an acute precipitating event in a patient with a chronic liver condition that injures hepatocytes leads to the accumulation of a cascade of inflammatory cytokines and results in further hepatic injury in the presence of failure of hepatocyte regeneration. The resulting compromise in immune function and liver decompensation leads to further susceptibility to infections, multi-organ failure, and death.
Patients will have features of acute hepatic decompensation. Also common are prolonged INR greater than or equal to 1.5, often elevated bilirubin and aminotransferases, thrombocytopenia with anemia, hypoglycemia, elevated ammonia, features of acute renal injury (with elevated serum creatinine), and abnormal electrolytes (hypokalemia, hypophosphatemia). Any imaging to support the clinical examination findings and ascertain infection or any organ involvement or organ failure may be required. Imaging of the brain, chest, abdomen, and pelvis should be considered. Abdominal imaging to determine the presence of features of portal hypertension, hepatocellular carcinoma, vascular thrombosis, lymph nodes, and spleen is vital. Abdominal sonogram with Doppler could be considered in patients with concomitant renal injury and vascular thrombosis. Brain imaging (CT or MRI) is helpful to rule out organic etiology of altered mental status, while chest imaging will help rule out pulmonary edema or pneumonia.
The management of ACLF consists of the prevention of precipitating factors leading to acute hepatic decompensation, supportive care, and early initiation of specific therapy, prevention, and management of complications. It also includes determining the prognosis and the need for liver support including possible liver transplantation. All patients should be hospitalized preferably at a center that has facilities and expertise for a liver transplant.
""Acute On Chronic Liver Failure (ACLF)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure (ACLF) pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure (ACLF) treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure (ACLF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure (ACLF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve Acute On Chronic Liver Failure (ACLF).
This segment of the Acute On Chronic Liver Failure (ACLF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute On Chronic Liver Failure (ACLF) Emerging Drugs
- HepaStem: Cellaion SA
- F573: Beijing Continent Pharmaceutical Co, Ltd.
Further product details are provided in the report……..
Acute On Chronic Liver Failure (ACLF): Therapeutic Assessment
This segment of the report provides insights about the different Acute On Chronic Liver Failure (ACLF) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute On Chronic Liver Failure (ACLF)
- There are approx. 4+ key companies which are developing the therapies for Acute On Chronic Liver Failure (ACLF). The companies which have their Acute On Chronic Liver Failure (ACLF) drug candidates in the most advanced stage, i.e. Phase II include, Cellaion SA.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Acute On Chronic Liver Failure (ACLF): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure (ACLF) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure (ACLF) drugs.
Acute On Chronic Liver Failure (ACLF) Report Insights
- Acute On Chronic Liver Failure (ACLF) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute On Chronic Liver Failure (ACLF) drugs?
- How many Acute On Chronic Liver Failure (ACLF) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute On Chronic Liver Failure (ACLF)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure (ACLF) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute On Chronic Liver Failure (ACLF) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cellaion SA
- Beijing Continent Pharmaceutical Co, Ltd.
- Grifols Therapeutics LLC
- HepaStem
- F573
- PE-A 5%
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Acute On Chronic Liver Failure (ACLF): Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Acute On Chronic Liver Failure (ACLF)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HepaStem: Cellaion SA
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Acute On Chronic Liver Failure (ACLF) Key Companies
- Acute On Chronic Liver Failure (ACLF) Key Products
- Acute On Chronic Liver Failure (ACLF)- Unmet Needs
- Acute On Chronic Liver Failure (ACLF)- Market Drivers and Barriers
- Acute On Chronic Liver Failure (ACLF)- Future Perspectives and Conclusion
- Acute On Chronic Liver Failure (ACLF) Analyst Views
- Acute On Chronic Liver Failure (ACLF) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
